Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Duchenne Muscular Dystrophy (DMD) Drugs Market

Duchenne Muscular Dystrophy (DMD) Drugs Market Trends

Report ID: GMI10182
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Duchenne Muscular Dystrophy Drugs Market Trends

Increasing research and development (R&D) funding significantly drives the DMD drugs market by catalyzing innovation and accelerating the development of novel therapies. Expanded funding supports enable pharmaceutical companies and research institutions to explore advanced treatment modalities such as gene therapy, exon skipping, and gene editing technologies.

For instance, in January 2023, Parent Project Muscular Dystrophy (PPMD) announced a strategic investment of USD 500,000 in Myosana Therapeutics Inc. to support the development and deployment of its non-viral gene therapy delivery platform. This initiative aimed to mitigate skeletal muscle degeneration and address DMD-related heart failure.
Thus, as DMD cases increase and R&D investments grow, the demand for effective treatments is expected to rise, potentially fostering market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The duchenne muscular dystrophy drugs market size was valued at USD 3.2 billion in 2023 and is estimated to grow at 11.6% CAGR between 2024 to 2032, driven by increasing burden of DMD and rising demand for novel therapies.

The corticosteroids segment of the market will account for USD 1.2 billion by 2032, attributed to their well-established efficacy in slowing the progression of the disease.

Asia Pacific duchenne muscular dystrophy drugs market held a decent share in 2023 and is poised to grow at 12% CAGR during 2024-2032, driven by increasing awareness and improved diagnostic capabilities.

Aurobindo Pharma, Capricor Therapeutics, Inc, Catalyst Pharmaceuticals Inc, EspeRare Foundation, and FibroGen, Inc. among others.